IVRN — Innoveren Scientific Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $5.58m
- $0.45m
Annual income statement for Innoveren Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.88 | 8.35 | 2.15 | 1.61 | 0.453 |
| Cost of Revenue | |||||
| Gross Profit | 5.52 | 6.29 | 1.38 | 0.907 | 0.336 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.1 | 38.9 | 7.94 | 6.2 | 7.76 |
| Operating Profit | -4.19 | -30.6 | -5.79 | -4.59 | -7.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.39 | -29.8 | -6.46 | -4.8 | -10.3 |
| Net Income After Taxes | -4.39 | -29.8 | -6.46 | -4.8 | -10.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.39 | -29.8 | -6.46 | -4.8 | -10.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.39 | -33.2 | -6.78 | -4.8 | -10.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -113 | -184 | -72.5 | -36.1 | -20.6 |